Sunitinib and Capecitabine for First Line Colon Cancer
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This study is for patients with metastatic colorectal cancer who have not been treated with
chemotherapy for their cancer. The purpose of this study is to find out if Capecitabine and
Sunitinib can be used together to improve progression-free survival in colorectal cancer.
All patients will take two medicines (Sunitinib and Capecitabine) by mouth every day until
their cancer gets worse.